A B Sousa, J P Fernandes, I Costa, G Ferreira, O Nunes, P Ribeiro, A Neves, E Cruz, F Aveiro, A S Rodrigues, M Bernardo, A Conduto, A J Gonçalves, A Monteiro, M Sousa, V H Soares, J Veiga, J Gouveia
{"title":"粒细胞-巨噬细胞集落刺激因子在急性髓性白血病缓解后治疗中的作用。","authors":"A B Sousa, J P Fernandes, I Costa, G Ferreira, O Nunes, P Ribeiro, A Neves, E Cruz, F Aveiro, A S Rodrigues, M Bernardo, A Conduto, A J Gonçalves, A Monteiro, M Sousa, V H Soares, J Veiga, J Gouveia","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The impact on occult leukemia of GM-CSF as a sensitizing agent has not been studied. We treated 41 adult patients with de novo acute myeloid leukemia, 25 of whom achieved complete remission and were given 1 to 3 post-remission courses, each course including GM-CSF begun 4 days prior to chemotherapy and given until day 3. After a median follow-up of 32 months, the probability of remaining in continuous complete remission was 17% at 46 months. GM-CSF in this setting was not associated with an improved outcome, arguing against a priming effect.</p>","PeriodicalId":73231,"journal":{"name":"Hematology and cell therapy","volume":"40 2","pages":"63-6"},"PeriodicalIF":0.0000,"publicationDate":"1998-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Granulocyte-macrophage colony-stimulating factor in post-remission therapy of acute myeloid leukemia.\",\"authors\":\"A B Sousa, J P Fernandes, I Costa, G Ferreira, O Nunes, P Ribeiro, A Neves, E Cruz, F Aveiro, A S Rodrigues, M Bernardo, A Conduto, A J Gonçalves, A Monteiro, M Sousa, V H Soares, J Veiga, J Gouveia\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The impact on occult leukemia of GM-CSF as a sensitizing agent has not been studied. We treated 41 adult patients with de novo acute myeloid leukemia, 25 of whom achieved complete remission and were given 1 to 3 post-remission courses, each course including GM-CSF begun 4 days prior to chemotherapy and given until day 3. After a median follow-up of 32 months, the probability of remaining in continuous complete remission was 17% at 46 months. GM-CSF in this setting was not associated with an improved outcome, arguing against a priming effect.</p>\",\"PeriodicalId\":73231,\"journal\":{\"name\":\"Hematology and cell therapy\",\"volume\":\"40 2\",\"pages\":\"63-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1998-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematology and cell therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology and cell therapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Granulocyte-macrophage colony-stimulating factor in post-remission therapy of acute myeloid leukemia.
The impact on occult leukemia of GM-CSF as a sensitizing agent has not been studied. We treated 41 adult patients with de novo acute myeloid leukemia, 25 of whom achieved complete remission and were given 1 to 3 post-remission courses, each course including GM-CSF begun 4 days prior to chemotherapy and given until day 3. After a median follow-up of 32 months, the probability of remaining in continuous complete remission was 17% at 46 months. GM-CSF in this setting was not associated with an improved outcome, arguing against a priming effect.
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
